• Publications
  • Influence
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
TLDR
This 'roadmap' for HGSOC was determined after extensive discussions at an Ovarian Cancer Action meeting in January 2015 and aims to reduce incidence and improve outcomes for women with this disease. Expand
Cutting Edge: Persistence of Transferred Lymphocyte Clonotypes Correlates with Cancer Regression in Patients Receiving Cell Transfer Therapy
TLDR
Analysis of the TCR β-chain V region gene products expressed in samples obtained from 25 patients treated with this protocol found a significant correlation between tumor regression and the degree of persistence in peripheral blood of adoptively transferred T cell clones, suggesting that inadequate T cell persistence may represent a major factor limiting responses to adoptive immunotherapy. Expand
Adoptive immunotherapy for cancer: building on success
TLDR
How a lymphopaenic environment enables tumour-reactive T cells to destroy large burdens of metastatic tumour and how the state of differentiation of the adoptively transferred T cells can affect the outcome of treatment are described. Expand
Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor
TLDR
CAR T cells bearing a functional chemokine receptor can overcome the inadequate tumor localization that limits conventional CAR targeting strategies and can significantly improve antitumor efficacy in vivo. Expand
Gene Transfer of Tumor-Reactive TCR Confers Both High Avidity and Tumor Reactivity to Nonreactive Peripheral Blood Mononuclear Cells and Tumor-Infiltrating Lymphocytes1
TLDR
It is demonstrated that the TCR appeared to be the core determinant of MART-1 Ag-specific cellular avidity in these activated T cells and that nonreactive PBMC or TIL could be made tumor-reactive with a specific and predetermined avidity. Expand
CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo.
TLDR
CD27 costimulation enhances expansion, effector function, and survival of human CAR-T cells in vitro and augments human T-cell persistence and antitumor activity in vivo. Expand
Chimeric Antigen Receptor T Cells with Dissociated Signaling Domains Exhibit Focused Antitumor Activity with Reduced Potential for Toxicity In Vivo
TLDR
A trans-signaling CAR-based immunotherapy strategy in which the T-cell activation signal is physically dissociated from the costimulatory signal in two CARs of differing antigen specificity can potentiate the therapeutic efficacy of CAR-T cells against cancer while minimizing parallel reactions against normal tissues bearing single antigen. Expand
CD137 Accurately Identifies and Enriches for Naturally Occurring Tumor-Reactive T Cells in Tumor
TLDR
A role for the TNFR-family member CD137 is revealed in the immunobiology of human cancer where it is preferentially expressed on tumor-reactive subset of TILs, thus rationalizing its agonistic engagement in vivo and its use in TIL selection for adoptive immunotherapy trials. Expand
The RET/PTC3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids.
TLDR
A new member of this fusion oncogene family, RET/PTC3, which has been implicated in more cases of solid tumor carcinoma than PTC1 or PTC2 and predominates in radiation-induced thyroid cancer of children, was investigated in this study. Expand
In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB).
TLDR
Results show that anti-FRα CAR outfitted with CD137 costimulatory signaling in tandem overcome issues of T-cell persistence and tumor localization that limit the conventional FRα T- cell targeting strategy to provide potent antitumor activity in vivo. Expand
...
1
2
3
4
5
...